Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives $46.43 Average Target Price from Brokerages

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) have been given a consensus recommendation of “Buy” by the ten ratings firms that are presently covering the company, MarketBeat Ratings reports. Eight analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $46.43.

Several equities research analysts recently commented on DNTH shares. TD Cowen began coverage on shares of Dianthus Therapeutics in a research note on Friday, December 20th. They set a “buy” rating on the stock. Oppenheimer upped their price target on Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an “outperform” rating in a research note on Monday, November 11th. HC Wainwright reiterated a “buy” rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a research note on Monday, November 11th. Finally, Raymond James raised Dianthus Therapeutics to a “moderate buy” rating in a research note on Thursday, December 12th.

Dianthus Therapeutics Stock Performance

Dianthus Therapeutics stock opened at $21.10 on Tuesday. Dianthus Therapeutics has a fifty-two week low of $17.41 and a fifty-two week high of $33.77. The stock has a market cap of $624.56 million, a price-to-earnings ratio of -8.44 and a beta of 1.74. The stock’s 50 day simple moving average is $23.11 and its two-hundred day simple moving average is $26.14.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The firm had revenue of $2.17 million during the quarter, compared to the consensus estimate of $1.07 million. On average, analysts predict that Dianthus Therapeutics will post -2.61 earnings per share for the current year.

Institutional Investors Weigh In On Dianthus Therapeutics

Several institutional investors have recently modified their holdings of DNTH. State Street Corp lifted its stake in Dianthus Therapeutics by 101.4% during the 3rd quarter. State Street Corp now owns 821,131 shares of the company’s stock valued at $22,483,000 after acquiring an additional 413,425 shares during the period. Janus Henderson Group PLC lifted its position in Dianthus Therapeutics by 40.5% during the third quarter. Janus Henderson Group PLC now owns 949,334 shares of the company’s stock valued at $25,936,000 after purchasing an additional 273,670 shares during the period. Point72 Asset Management L.P. boosted its holdings in Dianthus Therapeutics by 151.3% in the third quarter. Point72 Asset Management L.P. now owns 437,700 shares of the company’s stock worth $11,984,000 after purchasing an additional 263,500 shares during the last quarter. Great Point Partners LLC grew its position in Dianthus Therapeutics by 21.3% in the 2nd quarter. Great Point Partners LLC now owns 757,929 shares of the company’s stock worth $19,615,000 after purchasing an additional 132,929 shares during the period. Finally, Braidwell LP lifted its holdings in shares of Dianthus Therapeutics by 34.6% during the 3rd quarter. Braidwell LP now owns 493,687 shares of the company’s stock valued at $13,517,000 after buying an additional 126,836 shares during the period. 47.53% of the stock is owned by hedge funds and other institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.